Cassava Sciences stock breaks the benchmark and achieves an RS rating of over 80

The Rating of relative strength (RS). for Cassava Sciences (SAVA) hit a new percentile on Thursday, rising from 77 to 85.

X

In search of that The best stocks to buy and watchOne factor to watch closely is relative price strength.

This unique rating measures market leadership by showing how a stock’s price performance compares to the other stocks in our database over the last 52 weeks.

Over 100 years of market history shows that the best performing stocks typically have an RS rating of over 80 in the early stages of their development.

Learn how IBD helps you make more money in stocks

Cassava Sciences stock is not currently in a good buy position, despite recently reversing a downtrend. See if the stock forms a new pattern now after deleting several keys Moving averages. It’s nearing the 200-day mark, with a recent surge in traffic. Once a new pattern has formed, we can look for a clear entry point.

result report

Cassava Sciences reported 0% EPS growth in its most recent report, while revenue growth was 0%.

Cassava Sciences is ranked 292nd among its competitors in the Medical-Biomedical/Biotechnology industry group, which is currently in the top 20 out of 197 groups. Arcturus Therapeutics (ARC) And catalyst pharmaceuticals (CPRX) are also among the highest-rated stocks in the group.

​Stocks to buy and watch: top IPOs, big and small caps, growth stocks

YOU MAY ALSO LIKE:

Join IBD live and learn top chart reading and trading techniques from the pros
MarketSmith’s tools can help the individual investor
Profit from short-term trends with SwingTrader
Receive timely buy and sell alerts with the IBD Leaderboard
Find the best long-term investments with IBD Long-Term Leaders

IBD Digital: Get access to subscriber-only stock listings and market analysis. Plus, add the weekly print output for your weekend preparation.